In a CD-22 directed CAR-T cell therapy a small Phase-I trial was conducted with 3 Large B-cell lymphoma patients who had relapsed CD-19 directed CAR-T therapy and were given at least 2 prior lines of therapy Large B-cell lymphomas showed complete remission [54]. Here, CD22 is linked to B-cell non-Hodgkin lymphoma.